← boardnext 2026-09next 2027-09next 2028-03
CYTK
Cytokineticsdistress 7/10 · high distress / dilution risk$80.83-2%today-7% from 52w high
Lead: obstructive hypertrophic cardiomyopathy · target Cardiac myosin
Revenue
$19M
Liquidity
$130M
Runway
0.3 yrs
Shares 1y
+4%
Price & events
+24.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.7%
1D
+0.6%
1W
+1.0%
1M
+23.4%
3M
+27.5%
6M
+113.1%
1Y
+40.9%
2Y
+178.3%
5Y
+313.2%
All
Overview
- Market Cap
- $10.06B
- Enterprise Value
- $10.17B
- Volume
- 100.09K
- 52 Week Range
- $33.23 – $87.26
- Total Shares
- 124.43M
- Float Shares
- 123.87M
- Short %
- 20.01%
- % Held by Insiders
- 0.67%
- % Held by Institutions
- 118.82%
- RVOL
- 0.05x
- Beta
- 0.42
Pipeline stages · 3 programs
CK-4021586 (150 mg, 300 mg, 450 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Omecamtiv Mecarbil (OM)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Aficamten
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 6 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | CK-4021586 (150 mg, 300 mg, 450 mg | Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) | — | recruiting |
| 2027-09 Estimated 50% readout ~2027-11-15 | Phase 3 | Omecamtiv Mecarbil (OM) | Heart Failure, Heart Failure With Reduced Ejection Fraction | — | recruiting |
| 2028-03 Estimated 50% readout ~2028-05-15 | Phase 2/3 | Aficamten (5 - 20 mg) | Symptomatic Hypertrophic Cardiomyopathy (HCM) | — | enrolling by invitation |
| 2030-01 Estimated 50% readout ~2030-03-17 | Phase 2/3 | Aficamten | Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy | — | recruiting |
| 2026-06 | Phase 3 | Aficamten, Placebo | Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy | 500 | active not recruiting |
Show all 6 trials · 1 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-02-28 | Phase 3 | Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate | Obstructive Hypertrophic Cardiomyopathy (oHCM) | 175 | completed |
Catalyst news & presentations · 8
- PDUFA November 14, 2026Confirmed 100%PDUFAPDUFAaficamten · sNDA for aficamten based on MAPLE-HCM under reviewSEC 8-K
- 2026-08-06earningsEarningsEarnings releaseyahoo
- first quarter of 2026regulatory submissionFiled (NDA/BLA)aficamten · European Commission decision on marketing authorizationSEC 8-K
- Prescription Drug User Fee Act (PDUFA) target action date of December 26, 2025PDUFAPDUFAaficamten · FDA PDUFA target action date for aficamten NDA.SEC 8-K
- September 2, 2025conferencedata presentationsecondaryaficamten · Investor webcast to discuss MAPLE-HCM and other ESC 2025 dataSEC 8-K
- 2025-08-30safety signalaficamten · One death due to viral illness in aficamten arm.SEC 8-K
- June 2025filing acceptanceFiled (NDA/BLA)aficamten · Late Cycle meeting with FDA expected in June 2025.SEC 8-K
- 2025-04-29pdufa extensionaficamten · FDA extended PDUFA date to Dec 26, 2025 due to REMS being a Major AmendmentSEC 8-K
Approved drugs (1)
- MYQORZOAFICAMTEN2025 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $108 (+33% upside) · 20 analysts
- 2026-07-07RBC CapitalOutperform
- 2026-06-29UBSNeutral → Buy
- 2026-06-24MizuhoOutperform
- 2026-06-17NeedhamBuy
- 2026-05-19CitigroupBuy
- 2026-05-12JP MorganOverweight
Competitors — Cardiac myosin
- EWTXEdgewise Therapeutics, Inc.$4.1B · D4
Recent news
- 2026-07-20Cytokinetics, Incorporated (CYTK) Stock Analysis: Strong Analyst Support and 34% Potential Upside - DirectorsTalk Interviews
- 2026-07-18CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
- 2026-07-17Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-17Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-17New Cytokinetics hires receive stock awards with 3- and 4-year vesting - Stock Titan
- 2026-07-17Citi Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $99 - Moomoo
- 2026-07-16Form 4 Cytokinetics Inc For: 16 July By Investing.com - Investing.com Nigeria
- 2026-07-16Cytokinetics (CYTK) director Nancy Wysenski granted 75 fully vested shares - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.